Correlation Between Protalix Biotherapeutics and Alnylam Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Protalix Biotherapeutics and Alnylam Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protalix Biotherapeutics and Alnylam Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Protalix Biotherapeutics and Alnylam Pharmaceuticals, you can compare the effects of market volatilities on Protalix Biotherapeutics and Alnylam Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protalix Biotherapeutics with a short position of Alnylam Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protalix Biotherapeutics and Alnylam Pharmaceuticals.
Diversification Opportunities for Protalix Biotherapeutics and Alnylam Pharmaceuticals
0.62 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Protalix and Alnylam is 0.62. Overlapping area represents the amount of risk that can be diversified away by holding Protalix Biotherapeutics and Alnylam Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Alnylam Pharmaceuticals and Protalix Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protalix Biotherapeutics are associated (or correlated) with Alnylam Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Alnylam Pharmaceuticals has no effect on the direction of Protalix Biotherapeutics i.e., Protalix Biotherapeutics and Alnylam Pharmaceuticals go up and down completely randomly.
Pair Corralation between Protalix Biotherapeutics and Alnylam Pharmaceuticals
Considering the 90-day investment horizon Protalix Biotherapeutics is expected to generate 1.37 times more return on investment than Alnylam Pharmaceuticals. However, Protalix Biotherapeutics is 1.37 times more volatile than Alnylam Pharmaceuticals. It trades about 0.19 of its potential returns per unit of risk. Alnylam Pharmaceuticals is currently generating about 0.0 per unit of risk. If you would invest 169.00 in Protalix Biotherapeutics on November 27, 2024 and sell it today you would earn a total of 66.00 from holding Protalix Biotherapeutics or generate 39.05% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Significant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Protalix Biotherapeutics vs. Alnylam Pharmaceuticals
Performance |
| Timeline |
| Protalix Biotherapeutics |
| Alnylam Pharmaceuticals |
Protalix Biotherapeutics and Alnylam Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Protalix Biotherapeutics and Alnylam Pharmaceuticals
The main advantage of trading using opposite Protalix Biotherapeutics and Alnylam Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protalix Biotherapeutics position performs unexpectedly, Alnylam Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alnylam Pharmaceuticals will offset losses from the drop in Alnylam Pharmaceuticals' long position.| Protalix Biotherapeutics vs. Corvus Pharmaceuticals | Protalix Biotherapeutics vs. Aldeyra | Protalix Biotherapeutics vs. Checkpoint Therapeutics | Protalix Biotherapeutics vs. Cidara Therapeutics |
| Alnylam Pharmaceuticals vs. ProQR Therapeutics BV | Alnylam Pharmaceuticals vs. Wave Life Sciences | Alnylam Pharmaceuticals vs. Blueprint Medicines Corp | Alnylam Pharmaceuticals vs. Apellis Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Other Complementary Tools
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |